Boston, Mass. – June 7, 2014 – Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, announces that Dr. Alexander Buko has joined the executive team in a newly created position as Vice President of HMT America reporting to President Tsutotmu Hoshiba. “I am excited that Alex will be joining our team,” said Hoshiba. “Dr. Buko brings with him over 30 years of pharmaceutical experience with the FDA, Abbott Labs, and most recently with Biogen Idec where he held the position of Senior Director of Translational Medicine. Alex has successfully
led large scale omics projects in neurology, immunology, and oncology. With extensive experience in protein and metabolite based profiling, Alex will lead project management and
develop HMT’s biomarker-based platforms.” “I am very honored to join HMT and look forward to working with the research teams in both academia and pharmaceutical companies to further
enrich metabolic research,” said Buko. “HMT’s commitment to delivering quantitative and metabolic profiling will set the standard for discovery research to come.”

HMT is also pleased to announce F-SCOPE, a new C13 metabolite profiling platform. “F-SCOPE is the only quantitative C13 profiling assay commercially available,” says Dr. Laura Shelton, the
Scientific Project Coordinator. “This assay allows for the quantitative detection of over 55 labeled metabolites involved in central energy metabolism including glycolysis, the TCA cycle,
amino acids, purines, and glutathione, reporting C13 and C12 fractions for full flux and pathway-based analyses.” “F-SCOPE is ideal for analyzing biochemical networks and metabolic
perturbations,” says Dr. Buko. “The addition of F-SCOPE to CARCINOSCOPETM and other HMT services will provide another cutting edge quantitative research tool. The capability to deliver
unique quantitative and comparative metabolomics profiles is the hallmark of HMT.”

Tsuruoka, Japan, Nov. 22 ‐ Human Metabolome Technologies Inc., a metabolite discovery company, has announced today that the Japanese Patent Office (JPO) has issued Japanese patent number 5372213 titled: “The biomarker of depression, the measuring method for the biomarker of depression, and the program and storage for the diagnostic method” to the company for the discovery of biomarkers for depressive disorders. Ethanolamine
Phosphate (EAP) and the diagnostic method for its detection were discovered by HMT in collaboration with Dr. Noriyuki Kawamura.

The purpose of the present invention is to provide: a method to diagnose patients with the major depressive disorder by measuring single metabolic compounds, for example, ethanolamine phosphate (EAP), in blood samples. By using this method, the doctor can diagnose major depressive disorder with 82% sensitivity and 95% specificity.

“HMT has been creating a comprehensive patent portfolio for depressive disorders, oncology, and other applications. The issuance of this patent supports our overall intellectual property strategy and we continue to pursue additional patent applications in support of our diagnostic programs”, said Tsutomu Hoshiba, President, HMT America.

Cambridge, Mass., November 1, 2012 – Human Metabolome Technologies, Inc. (HMT), the leading provider of capillary electrophoresis mass spectrometry (CE‐MS) based metabolomics technology, today announced the opening of its first U.S. office in Cambridge, Mass.

The location of the office was based largely in part by the accessibility for globally competitive pharmaceutical companies and research institutions to HMT’s most important metabolome analysis services, CARCINOSCOPE, which was specifically designed for cancer research, and BASIC SCAN for more global, general‐purpose metabolomics research including biomarker discovery and companion diagnostics.

“Cambridge provides the perfect combination of academic and industrial arenas especially associated with the field of life science, food engineering, and environmental studies,” said
Tsutomu Hoshiba, President, HMT America. “HMT provides cutting‐edge solutions to life scientists, medical doctors, and pharmacologists via our state‐of‐the‐art metabolomics technology based on capillary electrophoresis mass spectrometry (CE‐MS), and we believe that Cambridge is the place to be for networking with businesses who will make the most of
our solutions.”